论文部分内容阅读
目的观察伊维菌素治疗蠕形螨病的效果及安全性。方法采用单盲、平行对照试验,将蠕形螨阳性者85例随机分成试验组和对照组,分别口服伊维菌素(IVMT)和新肤螨灵外用。伊维菌素为12mg(6mg/片),单次口服;新肤螨灵外用,每天早、晚各1次,连续6周。于第3周、第6周用透明胶纸法对其面部双侧鼻唇沟皮肤进行检查。结果在服药第3周末,伊维菌素对蠕形螨病的治愈率为74.42%(32/43),同期与对照组有显著性差异(P<0.05);在服药第6周末,伊维菌素对蠕形螨病的治愈率为100%(43/43),同期与对照组无显著性差异(P>0.05)。试验组未发生不良反应。结论伊维菌素治疗蠕形螨病安全有效。
Objective To observe the efficacy and safety of ivermectin in the treatment of Demodex disease. Methods A single blind and parallel controlled trial was used to divide 85 demodex positive patients into experimental group and control group randomly. IVMT and mites were given orally. Ivermectin 12mg (6mg / tablet), a single oral; Dermatophytum topical, daily morning and evening 1, for 6 weeks. In the third week, the sixth week with a transparent tape method on the facial bilateral nasolabial fold skin examination. Results At the end of the third week of treatment, the cure rate of ivermectin on Demodex was 74.42% (32/43), which was significantly different from the control group at the third week (P <0.05). At the end of the sixth week, The cure rate of mycotoxin to demodex disease was 100% (43/43), no significant difference with the control group (P> 0.05). No adverse reactions in the experimental group. Conclusion Ivermectin is safe and effective in the treatment of Demodex.